compounded semaglutide fda ruling alerts health care providers, compounders and patients of dosing errors associated with injectable products July 29, 2024: FDA issued

(242) reported that SCFA-producing probiotics not only reduce local gut inflammation but also exert systemic effects via the gut-lung axis, protecting against respiratory inflammation

DPP-4 inhibitors work by enhancing insulin secretion and reducing glucagon levels, while GLP-1 receptor agonists improve glucose control and promote weight loss, making them increasingly popular among patients with type 2 diabetes

Eric Okamoto, frequently consults with patients who have achieved significant weight reduction through GLP-1s and are seeking solutions to restore firmness, redefine contours, and feel confident in their new shape

and identification of rare but clinically significant irAEs

Cencioni, C